Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ 3rd, Rajkumar SV. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007 Jun 21;356(25):2582-90. PMID:17582068.

Kastritis E, Terpos E, et al. Validation of the Novel Criteria for the Definition of Symptomatic Myeloma: A Single Center Experience in 216 Patients with the Previous Diagnosis of Asymptomatic Disease. Blood 2015 126:4251

Dr. Robert A. Kyle

// Asymptomatic Myeloma Prognosis
var calc_output = [];

var bmp; 				// bone marrow plasmacytosis 
var smp; 				// serum monoclonal protein
var risk_group = '';	// risk group
var risk_percent = '';	// risk in percentage
var time = '';			// time to progression in years
var msg = ''; 			// message

if (bmp == 0 && smp == 0) {
	risk_group = 'High';
	risk_percent = '69%'; 
	msg = 'Risk of progression at 5 years 77% at 10 years 87% at 15 years';
	time = '27';
}
if (bmp == 0 && smp == 1) {
	risk_group = 'Intermediate';
	risk_percent = '43%'; 
	msg = 'Risk of progression at 5 years 64% at 10 years 70% at 15 years';
	time = '93';
}

if (bmp == 1 && smp == 0) {
	risk_group = 'Low';
	risk_percent = '15%';
	msg = 'Risk of progression at 5 years 33% at 10 years 39% at 15 years'; 
	time = '228';
}
if (bmp == 1 && smp == 1) {
	risk_group = '';
	risk_percent = ''; 
	msg = 'Patient does not meet criteria for asymptomatic myeloma (see Pearls/Pitfalls for criteria)';
	time = '';
}
if (bmp + smp < 2) {
calc_output.push({ // message on app
 name: 'mini',
 value: risk_group,
 value_text: 'risk',
 message: ""
});
}
if (bmp == 1 && smp == 1) {
calc_output.push({ // message on app
 name: 'mini',
 value: '',
 value_text: '',
 message: msg
});
}
if (bmp + smp < 2) {
calc_output.push({
 name: 'risk_group',
 value: risk_group,
 value_text: ' risk',
 message: ""
});
}
calc_output.push({
 name: 'risk',
 value: risk_percent,
 value_text: '',
 message: msg
});
if (bmp + smp < 2) {
calc_output.push({
 name: 'time',
 value: time,
 value_text: ' months',
 message: 'Median time to progression'
});
}

Asymptomatic Myeloma Prognosis

Predicts risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis.

Predicts risk of progression to active myeloma or amyloidosis.

Randall (Randy) Pierce is in private practice with Northwest Georgia Oncology Centers in Carrollton, Georgia, where he has been in practice since 1998. After graduating from the University of Georgia in 1988, he attended medical school at the Medical College of Georgia. His internal medicine residency and hematology/oncology training were completed at Wake Forest University/Baptist Medical Center in 1998. Dr. Pierce treats most malignancies and has a special interest in myeloma and lymphoma. He is married, has 3 children, and enjoys playing tennis and deep sea fishing.

Randall Pierce, MD

The Asymptomatic Myeloma Prognosis predicts risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis.

Revised Myeloma ISS

Multiple Myeloma Diagnostic Criteria

Multiple Myeloma Response Criteria

EB Medicine is the premier provider of evidence-based clinical content and CME resources for emergency medicine practitioners.

Listen to the VACO co-creators break down how to use VACO\, what it does\, and what it doesn’t.

Calc Function